The impact of body weight on rivaroxaban pharmacokinetics

Essentials The optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known. A pharmacokinetic study was conducted based in real‐world patients in a London teaching hospital. In the cohort of patients studied, weight on its own did not impact significantly on rivaroxaban pharmacokinetics. A larger study with patients in the weight categories of interest from the real‐world population is required to further clarify the situation.

[1]  L. Alberio,et al.  Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery , 2017, British journal of clinical pharmacology.

[2]  J. Sterne,et al.  Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. , 2017, Health technology assessment.

[3]  J. Sterne,et al.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. , 2017, Health technology assessment.

[4]  R. Reynolds,et al.  Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. , 2016, Thrombosis research.

[5]  M. Prins,et al.  Treatment of venous thromboembolism with rivaroxaban in relation to body weight , 2016, Thrombosis and Haemostasis.

[6]  P. Sandset,et al.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  A. Camm,et al.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.

[8]  L. Couchman,et al.  New oral anticoagulants: dosing and monitoring , 2015, BMJ : British Medical Journal.

[9]  J. Robert Powell.  Are new oral anticoagulant dosing recommendations optimal for all patients? , 2015, JAMA.

[10]  L. Couchman,et al.  Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry , 2014, Therapeutic drug monitoring.

[11]  J. Beyer-Westendorf,et al.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. , 2014, Blood.

[12]  W. Mueck,et al.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban , 2013, Clinical Pharmacokinetics.

[13]  A. Vermeulen,et al.  Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. , 2012, British journal of clinical pharmacology.

[14]  P. Prandoni,et al.  Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention , 2011, Clinical Pharmacokinetics.

[15]  R. Arya,et al.  Anticoagulating obese patients in the modern era , 2011, British journal of haematology.

[16]  S. Duffull,et al.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. , 2011, British journal of clinical pharmacology.

[17]  Bengt I Eriksson,et al.  Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement , 2008, Thrombosis and Haemostasis.

[18]  S. Duffull,et al.  Dosing in Obesity: A Simple Solution to a Big Problem , 2007, Clinical pharmacology and therapeutics.

[19]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[20]  W. Mueck,et al.  Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects , 2007, Journal of clinical pharmacology.

[21]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[22]  T. Weinstein,et al.  Glomerular hemodynamics in severe obesity. , 2000, American journal of physiology. Renal physiology.

[23]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[24]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[25]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[26]  W. Ageno,et al.  Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. , 2016, The Lancet. Haematology.

[27]  Paolo Prandoni,et al.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. , 2011, Clinical pharmacokinetics.

[28]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[29]  M. Gent,et al.  Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery , 2008, Clinical pharmacokinetics.

[30]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[31]  The National Institute for Clinical Excellence. , 2001, Nursing management.

[32]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.